NCT00915278 - A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Advanced Non-Hematologic Malignancies

Interventions

DRUG

PF-04605412

PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal

Trial Locations (7)

19111

Pfizer Investigational Site, Philadelphia

37232

Pfizer Investigational Site, Nashville

37232-5536

Pfizer Investigational Site, Nashville

37232-7610

Pfizer Investigational Site, Nashville

SW17 0QT

Pfizer Investigational Site, Tooting

SM3 9DW

Pfizer Investigational Site, North Cheam

SM2 5PT

Pfizer Investigational Site, Sutton